GSK cancer drug Votrient gets FDA approval for soft tissue sarcoma

GlaxoSmithKline‘s (NYSE:GSK) kidney cancer drug Votrient now has U.S. Food and Drug Administration approval to treat another indication — advanced soft tissue sarcoma. Drug approval means…
Read the full story: MedCity News